早期声门癌SABR的Ⅰ期研究:设计与初步结果
该Ⅰ期研究评估早期声门癌立体定向消融放疗(SABR)的安全性与可行性,报告前两个剂量组初步结果。第一剂量组7例接受59.5 Gy/3.5 Gy/次,第二剂量组5例接受55 Gy/5 Gy/次;中位随访17.5个月未出现3级及以上毒性。第二剂量组1例放疗后4个月原发灶复发并全喉切除,其余无瘤生存;嗓音与生活质量无显著变化。
要点
- 早期声门癌SABR前两剂量组未出现3级及以上毒性
- 第二剂量组1例放疗后4个月原发灶复发并全喉切除
- 放疗后6个月嗓音指标与生活质量无显著变化
核心结论
- 大分割VMAT 3.5 Gy与5 Gy分次方案毒性可接受,嗓音结局与生活质量尚可。
研究设计与样本
- Ⅰ期研究,第一剂量组7例接受59.5 Gy/3.5 Gy/次,第二剂量组5例接受55 Gy/5 Gy/次。
- 剂量限制性毒性定义为3级及以上治疗相关毒性。
主要发现
- 中位随访17.5个月(范围1.7–30.6个月)内无患者出现3级及以上毒性。
- 第二剂量组1例放疗后4个月原发灶复发并接受全喉切除,其余患者局部区域及远处无瘤。
- 放疗后6个月Jitter、Shimmer、平均发声时间及噪声谐和比无显著变化;HNCI评分治疗前后无显著差异(P=0.221)。
关键数值与推荐
- 分次剂量从3.5 Gy(总剂量59.5 Gy)递增至9 Gy(总剂量45 Gy)。
- 目前研究继续以55 Gy/11次和45 Gy/5次进行。
- 证据等级2b。
临床怎么用
- 早期声门癌行大分割VMAT的SABR方案需在Ⅰ期研究中继续评估安全性与可行性。
局限性
- 本文仅报告第一和第二剂量组初步结果,样本量小,随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Avoidance of organs at risk has become possible with advances in image-guided volumetric-modulated arc therapy (VMAT) techniques. This study was designed to evaluate the safety and feasibility of stereotactic ablative radiotherapy (SABR) for early stage glottic cancer. This report presents the preliminary result of the first and second dose level. METHODS: Fraction size was increased from 3.5 gray (Gy) (total dose 59.5 Gy) to 9 Gy (total dose 45 Gy). Dose-limiting toxicities were defined as grade 3 or higher treatment-related toxicities. Voice outcome was assessed with electroglottography, and quality of life (QoL) was measured with the Head and Neck Cancer Inventory (HNCI). RESULTS: Seven patients received 59.5 Gy at 3.5 Gy per fraction as the first dose level, and five patients received 55 Gy at 5 Gy per fraction as the second dose level. None of the patients developed grade 3+ toxicity throughout a median follow-up of 17.5 months (range, 1.7-30.6 months). One patient in the second dose level recurred in the primary site at 4 months after radiotherapy (RT) and received total laryngectomy. The rest of participants were disease-free at locoregional and distant sites. Jitter, shimmer, mean phonation time, and noise-to-harmony ratio did not change significantly at 6 months after RT. HNCI scores between pretreatment and posttreatment were not significantly different (P = 0.221). CONCLUSION: This study revealed acceptable toxicity, voice outcome, and QoL in patients treated with hypofractionated VMAT of 3.5 Gy and 5 Gy per fraction. This phase I study is currently ongoing with a dose of 55 Gy in 11 fractions and 45 Gy in five fractions. LEVEL OF EVIDENCE: 2b. Laryngoscope, 2560-2565, 2018.
引用
- Yu T, Wee CW, Choi N, et al. Study design and early result of a phase I study of SABR for early-stage glottic cancer. Laryngoscope. 2018. PMID: 29756264. doi:10.1002/lary.27226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。